United States Patent 4,597,961: Scope, Claims, Expiration, and Nicotine-Delivery Patent Landscape

U.S. Patent No. 4,597,961 covers methods of administering nicotine through the skin with an occlusive patch containing liquid nicotine. Its claims require both a transdermal smoking-cessation or nicotine-maintenance method and a defined patch architecture. The patent issued July 1, 1986, and its ordinary 17-year term expired July 1, 2003, assuming no unusual term adjustment or extension. It therefore does not present a current U.S. blocking right for nicotine patches. [1]

The patent remains relevant as prior art because it predates commercial nicotine-replacement patches and discloses core concepts later used in nicotine transdermal systems: an impermeable backing, a nicotine-permeable membrane, a nicotine reservoir, occlusion, behind-the-ear application, and smoking-cessation dosing.

What does U.S. Patent 4,597,961 protect?

The patent protects a transdermal nicotine administration method rather than nicotine itself. The independent claims require:

Administration through the skin.
Use of an occlusive pad adhered to the skin.
A nicotine-impermeable backing.
A nicotine-containing cavity or absorbent material.
A dosage sufficient to satisfy nicotine dependence or approximately replicate smoking exposure.
In several claims, a specific membrane or reservoir structure.

Claims 1 and 16 define two principal patch configurations:

Claim group	Required patch structure	Principal use
Claims 1-15	Impermeable backing, nicotine-permeable porous inert membrane, cavity containing liquid nicotine	Satisfying nicotine dependence or assisting smoking cessation
Claims 16-19	Impermeable backing defining a cavity and absorbent material containing absorbed nicotine	Satisfying nicotine dependence or assisting smoking cessation

The claims do not broadly cover every nicotine patch. A patch that lacks the claimed cavity, membrane, absorbent reservoir, or occlusive backing may fall outside the literal scope of the issued claims.

When did U.S. Patent 4,597,961 expire?

The patent issued on July 1, 1986. For a pre-June 8, 1995 U.S. patent, the ordinary term was 17 years from grant. On that basis, the expected expiration date was July 1, 2003. [1][2]

Event	Date
U.S. patent issuance	July 1, 1986
Ordinary patent term	17 years from issuance
Expected expiration	July 1, 2003
Current enforceability	Expired
Patent-term extension relevant to ordinary nicotine patches	None apparent

The patent predates the modern U.S. patent-term rule of 20 years from the earliest effective nonprovisional filing date. Patent-term adjustment also generally does not alter the analysis for this generation of patent in a commercially material way. Patent expiration eliminates enforcement risk based on this patent, although the disclosure can remain important in validity and freedom-to-operate analyses involving later patents.

How are the claims divided between the two patch designs?

Claims 1-15: liquid nicotine reservoir and porous membrane

Claim 1 requires an occlusive pad with:

A nicotine-impermeable backing;
A nicotine-permeable, porous, inert membrane;
A cavity between the backing and membrane; and
Liquid nicotine in the cavity.

Claims 2 and 3 narrow the nicotine formulation. Claim 2 covers nicotine base without solvent, vehicle, or carrier. Claim 3 covers nicotine base diluted with a pharmaceutically acceptable carrier, solvent, or vehicle that reduces skin penetration.

Claim 4 specifies application behind the ear. Claim 5 limits the patch to 1-4 microliters of nicotine base. Claim 6 specifies a blood concentration or dosage expression of 15-25 nanograms per liter. Claims 7-15 add physical addiction, smoking cessation, repeated administrations, and related limitations.

The strongest structural limitation in this group is the combination of a separate porous membrane and a cavity containing liquid nicotine. A modern matrix patch in which nicotine is dispersed through a polymer layer, rather than held as liquid in a cavity behind a membrane, may avoid literal infringement of these limitations.

Claims 16-19: absorbent-material reservoir

Claim 16 covers a different structure. The pad has:

A nicotine-impermeable backing defining a cavity; and
An absorbent material inside the cavity with nicotine absorbed into it.

This claim does not expressly require the porous inert membrane recited in claim 1. Claims 17 and 19 specify 1-4 microliters of nicotine base. Claim 18 applies the structure to smoking cessation.

The distinction matters for claim construction. A patch may avoid claims 1-15 because it lacks the specified membrane while still raising a historical issue under claim 16 if it uses an absorbent reservoir inside an impermeable-backed cavity. Because the patent is expired, this distinction has no current infringement consequence.

What are the key limitations of the independent claims?

Claim 1 limitations

Claim 1 is a method claim. A qualifying act would require performance of the claimed nicotine administration method using the specified patch structure. The relevant limitations are cumulative:

Limitation	Scope implication
“Administering nicotine”	Requires delivery of nicotine, not merely possession or manufacture
“Satisfying a nicotine habit”	Limits the stated therapeutic purpose
“Transdermally administering”	Requires skin-mediated delivery
“Occlusive pad adhered to the skin”	Requires an adhered, occluding delivery device
Impermeable backing	Requires resistance to nicotine passage through the backing
Porous, inert, nicotine-permeable membrane	Requires a specific membrane component
Cavity between backing and membrane	Requires a reservoir space
Liquid nicotine in cavity	Excludes many dry matrix and adhesive-dispersion designs

The preamble language concerning minimizing or eliminating pulmonary side effects may create additional claim-construction issues. Courts often assess whether such language limits the claim, particularly where it states the purpose of the method rather than merely identifying an intended use. The enforceable scope would depend on the intrinsic record, including the specification and prosecution history.

Claim 8 limitations

Claim 8 is directed to assisting a person to quit smoking. It requires transdermal delivery at a rate approximately the same as nicotine exposure from smoking and repeats the membrane, cavity, and liquid-nicotine requirements of claim 1.

This claim is narrower in stated purpose but potentially broader in dosing language because “approximately the same” may require expert evidence and pharmacokinetic interpretation. The term is less precise than the numerical range in claim 14.

Claim 16 limitations

Claim 16 covers the absorbent-reservoir design and does not require the porous membrane. Its critical limitations are the backing, cavity, absorbent material, and absorbed nicotine. A patch using a nicotine-containing adhesive layer without a distinct cavity or absorbent insert would present a weaker literal infringement case.

What do the dependent claims add?

Claims	Added limitation
2, 11	Nicotine base without solvent, vehicle, or carrier
3, 12	Nicotine base diluted with a pharmaceutically acceptable carrier, solvent, or vehicle
4, 13	Application behind the ear
5, 10, 17, 19	1-4 microliters of nicotine base
6, 14	Blood dosage or concentration of 15-25 nanograms per liter
7, 15	Administration to a physically nicotine-addicted patient
9	Repeated transdermal administration interspersed with cigarettes

Claim 9 is particularly narrow. It requires a sequence in which transdermal administrations are interspersed with cigarettes to reduce the reinforcing effect of non-pharmacological smoking factors. A standard continuous nicotine-patch regimen without cigarettes would not satisfy this limitation.

The numerical limitations also raise measurement questions. The claims use “nanograms per liter of blood,” while nicotine pharmacokinetic data are commonly reported as plasma concentration in nanograms per milliliter. Any historical infringement or validity analysis would need to address whether the patent’s unit reflects the original disclosure, a drafting error, or an intended concentration range.

What formulations are protected by U.S. Patent 4,597,961?

The claims cover three formulation approaches:

Liquid nicotine base without a carrier.
Nicotine base diluted with a carrier, solvent, or vehicle that reduces penetration.
Nicotine absorbed into an absorbent material.

The patent does not claim every nicotine formulation. It does not expressly claim:

Nicotine polacrilex gum;
Nicotine lozenges;
Nicotine nasal sprays;
Nicotine inhalers;
Oral nicotine pouches;
Nicotine salts as a broad class;
A polymeric matrix without the claimed cavity architecture; or
A drug-in-adhesive system lacking the claimed reservoir structure.

The formulation disclosure is commercially important because modern nicotine patches commonly use controlled-release matrices or drug-in-adhesive systems rather than a simple liquid nicotine reservoir. Later patents could therefore obtain protection around polymer composition, adhesive chemistry, release control, skin adhesion, stability, packaging, and manufacturing even though the foundational concepts were disclosed in the '961 patent.

How strong was the patent estate for nicotine patches?

The '961 patent was conceptually broad but technically narrow in several respects. Its strongest features were the early disclosure of transdermal nicotine and the detailed relationship between occlusion, nicotine loading, skin placement, and smoking cessation. Its weaknesses were the dependence on a specific patch structure and the method-claim format.

Strength factors

Early priority in transdermal nicotine delivery.
Direct linkage between nicotine delivery and smoking cessation.
Disclosure of behind-the-ear administration.
Coverage of both liquid-reservoir and absorbent-reservoir designs.
Dependent claims addressing nicotine concentration and dose.

Weakness factors

Structural limitations may exclude later matrix and adhesive systems.
Method claims require proof that a person performed the claimed administration.
“Sufficient to satisfy” and “approximately the same” create interpretation issues.
The claimed blood-dose language is technically unusual.
Several concepts may have been vulnerable to obviousness arguments based on earlier transdermal drug-delivery technology and known nicotine pharmacology.
The patent expired in 2003.

The patent was therefore more important as an early platform disclosure than as a long-term exclusionary asset.

What was the later patent landscape for nicotine replacement therapy?

The later landscape divided into several patent categories:

Patent category	Typical protected subject matter
Reservoir patches	Liquid nicotine, membranes, backing layers, rate control
Matrix patches	Nicotine dispersed in polymer or adhesive matrices
Drug-in-adhesive patches	Adhesive composition, nicotine loading, skin adhesion
Release-control patents	Membrane permeability, diffusion rate, multilayer structures
Formulation patents	Nicotine salts, solvents, stabilizers, penetration enhancers
Manufacturing patents	Coating, drying, lamination, pouching, and quality control
Method-of-use patents	Smoking cessation schedules, dose tapering, combination therapy
Product-design patents	Patch dimensions, placement, backing, liners, and packaging

Commercial nicotine-patch products were associated with companies including Ciba-Geigy, SmithKline Beecham, Novartis, GlaxoSmithKline, and later generic manufacturers. Product-specific patent portfolios varied by brand, formulation, and market.

Later patents generally sought to distinguish their inventions from simple liquid nicotine reservoirs by claiming controlled release, improved adhesion, reduced irritation, reduced nicotine crystallization, improved stability, or a matrix that eliminated the need for a liquid cavity.

What was the FDA and Orange Book status of nicotine patches?

FDA-approved nicotine replacement therapy products include transdermal systems, chewing gum, lozenges, nasal sprays, and inhalation products. The nicotine patch is regulated as an approved drug product, historically through new drug applications and later abbreviated applications for generic products. [3]

The Orange Book lists patents and exclusivity associated with specific approved drug products, not all patents that may relate to a therapeutic category. A patent is not enforceable merely because it appears in the Orange Book, and absence from the Orange Book does not by itself resolve every patent issue.

U.S. Patent 4,597,961 is expired and cannot presently block an FDA applicant. Any historical listing associated with a nicotine product would have ceased to create a live patent barrier upon expiration. Current approval issues for nicotine patches typically concern bioequivalence, adhesion, drug release, manufacturing controls, labeling, and product-specific patents rather than the '961 patent. [3][4]

Were Paragraph IV challenges relevant to this patent?

Paragraph IV litigation is no longer relevant to the expired '961 patent. During its term, a generic applicant could have challenged a listed patent by certifying that the patent was invalid, unenforceable, or would not be infringed. Under the Hatch-Waxman framework, a Paragraph IV notice could trigger patent litigation and a potential 30-month stay of FDA approval. [2]

For nicotine patches, Paragraph IV risk would generally have centered on:

Whether the generic used the same reservoir or matrix structure;
Whether the asserted claims were listed for the reference product;
Whether a method-of-use claim was carved out through labeling;
Whether the patent was invalid for anticipation or obviousness; and
Whether the generic product had an equivalent release profile.

The '961 claims are method claims with device limitations. A generic applicant could have pursued a noninfringement position based on a matrix or adhesive design that lacked the claimed cavity and membrane.

What generic entry risks exist for nicotine patches?

The expired patent creates no current entry risk. Current risks arise from later patents and regulatory requirements.

Generic patch entry

A generic transdermal nicotine product generally must establish pharmaceutical equivalence and bioequivalence or otherwise satisfy FDA requirements applicable to the proposed product. Critical technical comparisons include:

Nicotine content;
Release rate;
Adhesion;
Residual nicotine;
Skin permeation;
Patch dimensions;
Wear duration;
Manufacturing consistency; and
Labeling for smoking cessation.

Biosimilar risk

Biosimilar analysis does not apply to nicotine. Nicotine is a small-molecule active ingredient, not a biologic subject to the Public Health Service Act biosimilar pathway. Generic competition proceeds through the Federal Food, Drug, and Cosmetic Act, generally under the ANDA framework. [2][3]

What patent litigation or settlements affected U.S. Patent 4,597,961?

The supplied claims do not identify litigation, settlement agreements, assignments, terminal disclaimers, reexaminations, or post-grant proceedings. The patent’s expiration means any historical litigation would now have no prospective exclusionary effect. Current freedom-to-operate work should focus on later U.S. patents covering specific nicotine-patch formulations, adhesives, release systems, manufacturing processes, and approved-product labeling.

An expired foundational patent can still affect litigation indirectly. Defendants may cite it as prior art against later claims directed to transdermal nicotine, occlusive patches, nicotine reservoirs, behind-the-ear delivery, or smoking-cessation dosing.

How does the '961 patent compare with modern nicotine patches?

Issue	U.S. 4,597,961	Modern nicotine patch
Core architecture	Liquid reservoir or absorbent cavity	Often matrix or drug-in-adhesive
Backing	Nicotine-impermeable	Commonly present, but materials vary
Rate control	Porous membrane and skin delivery	Polymer, adhesive, membrane, or multilayer control
Nicotine form	Nicotine base, with or without carrier	Formulated nicotine base with excipients
Placement	Behind the ear expressly claimed	Commonly upper arm, chest, back, or hip
Use	Habit satisfaction and smoking cessation	Smoking cessation, usually once-daily therapy
Patent status	Expired	Later product and process patents may remain relevant
Regulatory pathway	Foundational disclosure	NDA, ANDA, labeling, bioequivalence, and quality requirements

A modern patch that uses a nicotine-containing adhesive matrix may practice the broad concept of transdermal nicotine delivery but avoid the literal structural limitations of claims 1-15 and 16-19.

What is the commercial significance of the expired patent?

The commercial value of the '961 patent was historical rather than current. The patent disclosed a practical route to nicotine replacement before transdermal nicotine became an established over-the-counter therapy. It helped define the technical and clinical concepts later used in products such as Nicoderm, Habitrol, and generic nicotine patches.

Revenue exposure today is therefore indirect. No current nicotine-patch revenue should be attributed to enforceable rights under the '961 patent. Commercial exposure instead depends on:

Brand strength;
FDA-approved labeling;
Retail and pharmacy distribution;
Patch adhesion and tolerability;
Generic pricing;
Consumer switching;
Manufacturing scale; and
Any unexpired follow-on patents.

Key Takeaways

U.S. Patent 4,597,961 covers methods of transdermal nicotine administration using specific occlusive patch structures.
Claims 1-15 focus on a liquid nicotine cavity separated from the skin by a porous, inert, nicotine-permeable membrane.
Claims 16-19 cover an absorbent material containing nicotine inside a cavity defined by an impermeable backing.
Dependent claims add nicotine base, carriers, behind-the-ear placement, 1-4 microliters of nicotine, blood-dose limitations, physical addiction, and cigarette-interspersed dosing.
The patent issued July 1, 1986, and its ordinary term expired July 1, 2003.
It presents no current U.S. infringement barrier or Paragraph IV obstacle.
The patent does not broadly cover all nicotine patches, nicotine formulations, nicotine gum, lozenges, inhalers, oral pouches, or modern matrix systems.
Nicotine is a small molecule, so biosimilar analysis does not apply.
Current freedom-to-operate risk lies in later formulation, adhesive, release-control, manufacturing, and product-specific patents.

FAQs

Does U.S. Patent 4,597,961 cover nicotine gum or nicotine lozenges?

No. The claims require transdermal administration through an adhered occlusive pad. Oral nicotine products do not satisfy those core limitations.

Does the patent cover every nicotine patch placed behind the ear?

No. Behind-the-ear placement is a dependent limitation in claims 4 and 13. The independent claims also require particular reservoir or absorbent structures, so placement alone is insufficient.

Can a modern nicotine matrix patch infringe the '961 patent?

The patent is expired, so there is no current infringement liability. As a historical claim-construction matter, a matrix patch may lack the claimed cavity containing liquid nicotine or the claimed absorbent material.

Was U.S. Patent 4,597,961 an Orange Book patent?

An Orange Book listing cannot be established from the claims alone. In any event, the patent expired in 2003 and cannot currently delay FDA approval or support an infringement action.

Are nicotine-patch manufacturers exposed to biosimilar competition?

No. Nicotine is a small-molecule drug. Competition is governed by generic-drug pathways, including ANDA procedures, rather than the biosimilar pathway.

References

U.S. Patent No. 4,597,961. (1986). Transdermal nicotine. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
U.S. Code, 35 U.S.C. §§ 154, 156 (2024).
U.S. Code, 21 U.S.C. §§ 355, 505(j) (2024).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	143277	⤷ Start Trial
Austria	88366	⤷ Start Trial
Germany	3650575	⤷ Start Trial
Germany	3688329	⤷ Start Trial
Germany	498468	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,597,961

Summary for Patent: 4,597,961